NCT02863991 2024-07-03Oral ONC201 in Relapsed/Refractory Multiple MyelomaJazz PharmaceuticalsPhase 1/2 Terminated17 enrolled 10 charts
NCT02609230 2021-06-04A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple MyelomaFox Chase Cancer CenterPhase 1 Completed33 enrolled